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Available online 2 April 2016Introduction: Patients with peritoneal dissemination of pancreatic adenocarcinoma do not beneﬁt from surgical
resection, but radiologic and cytologic detection of peritoneal cancer lack sensitivity. This trial sought to deter-
mine if an oncolytic virus may be used as a diagnostic agent to detect peritoneal cancer.
Methods: Peritonealwashings frompatients with pancreatic adenocarcinomawere incubatedwith the enhanced
green ﬂuorescent protein (eGFP)-expressing oncolytic herpes simplex virus (HSV) NV1066. eGFP-positive or
negative status was recorded for each specimen and compared to results obtained by conventional cytologic
evaluation. These results were correlatedwith recurrence and survival for patients who underwent R0 resection.
Results: Of 82 patients entered in this trial, 12 (15%) had positive cytology and 50 (61%) had virally-mediated
eGFP positive cells in peritoneal washings. All cytology-positive patients were also eGFP positive. HSV-
mediated ﬂuorescence detection had sensitivities of 94% and 100% for detection of any and peritoneal metastatic
disease; respectively. Median recurrence free and disease speciﬁc survival were 6.5 and 18.3 months for eGFP
positive patients, versus 12.2 and 36.2 months for eGFP negative patients (P= 0.01 and 0.19); respectively.
Conclusions: A geneticallymodiﬁedHSV can be used as a highly sensitive diagnostic agent for detection ofmicro-
metastatic disease in patients with pancreatic adenocarcinoma and may improve patient selection for surgery.







Pancreatic cancer is a highly aggressive disease with dismal progno-
sis. Patients with localized disease beneﬁt from multimodality therapy
including surgical resection. Patients with metastatic disease, however,
gain no beneﬁt from a potentially morbid surgical procedure. Staging
laparoscopy (SL) has been shown to identify occult metastatic disease
in 14% to 31% of patients, effectively sparing these patients unnecessary,
aggressive therapies (Ahmed et al., 2006; Doucas et al., 2007; Enestvedt
et al., 2008; Jimenez et al., 2000a, b;White et al., 2008). One component
of DL that is increasingly acknowledged as important is the cytological
analysis of peritoneal cells harvested. Free cancer cells in the peritone-
um are thought to arise from exfoliation of malignant cells from the pri-
mary tumor and their presence is thought to lead to the peritoneum as a
frequent site of recurrence (Foo et al., 1993; Gold et al., 2007). Patients
with positive peritoneal cytology (PPC) as the only evidence ofmetasta-
sis have the same outcome as patients with grossly visible metastases
(Ferrone et al., 2006; Merchant et al., 1999). Thus, the American Jointuarte Road, Duarte, CA 91010,
ss article under the CC BY-NC-ND licCommission on Cancer (AJCC) staging system for pancreatic cancer in-
cludes PPC as a criterion for M1 disease.
While conventional cytology is currently the gold standard for de-
tection of malignant cells in peritoneal ﬂuid because it is both highly
speciﬁc and clinically relevant, it is thought to lack sensitivity, Many pa-
tientswith negative peritoneal cytology at the time of resectionwith cu-
rative intent still develop early intraperitoneal recurrence(Abe et al.,
1995; Kodera et al., 2005; Selvaggi, 2003). Additional techniques includ-
ing immunohistochemistry (IHC), microarray analysis, and reverse-
transcription polymerase chain reaction (RT-PCR) for tumor markers
have been investigated to improve the sensitivity of detection of perito-
neal cancer cells (Kodera et al., 2002, 2005; Dalal et al., 2007; Fukumoto
et al., 2006; Hoffmann et al., 2007; Katsuragi et al., 2007; Mori et al.,
2007; Oyama et al., 2004; Tamura et al., 2007; To et al., 2003; Zhang
et al., 2006; Schmidt et al., 2001). Limitations of these techniques in-
clude cost and time consumingnature of their use, and lack of reproduc-
ibility. RT-PCR is also limited by its exquisite sensitivity, which can lead
to false-positive, clinically irrelevant results (Timar et al., 2002;
Kammula et al., 2004; Wong and Coit, 2012).
Viral oncolytic therapy is a ﬁeld that seeks to genetically design vi-
ruses that speciﬁcally infect, replicate within, and kill cancers. Many
promising viruses so designed are now in clinical trials as cancerense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
95K.J. Kelly et al. / EBioMedicine 7 (2016) 94–99therapy (Geevarghese et al., 2010; Heo et al., 2013; Kaufmann and
Chiocca, 2014; Kemeny et al., 2006; Reid et al., 2001). The herpes-
based virus, T-VEC, recently became the ﬁrst oncolytic virus approved
for clinical use in the Western world for the treatment of metastatic
melanoma. NV1066 is a replication-competent, tumor speciﬁc herpes
virus that carries themarker gene encoding enhanced green ﬂuorescent
protein (eGFP). In vitro, NV1066 has been shown to infect over 111 dif-
ferent human cancer cell lines, and can detect as few as 1 cancer cell in a
background of 1million normal cells (Adusumilli et al., 2011). In animal
models, NV1066 can circulate the blood stream and identify occult met-
astatic deposits of cancer (Adusumilli et al., 2005, 2006a, b; Eisenberg
et al., 2006; Stanziale et al., 2004). The aim of the current study was to
evaluate use of this virus in rapid detection of peritoneal dissemination
of pancreatic cancer. This human clinical trial sought to determine if the
presence of virally-detected, rare peritoneal cancer cells predict perito-
neal recurrence and patient outcome.
2. Methods
2.1. Virus
NV1066 is a replication-competent, attenuated oncolytic HSV type 1
(HSV-1), derived from wild-type HSV-1 (F strain) as previously de-
scribed (Wong et al., 2002). This virus was attenuated by deletions of
UL23, an internal repeat sequence containing single copies of the
genes encoding ICP-0, ICP-4, and the ICP34.5 neurovirulence gene.
This virus also carries the marker gene for eGFP, which ﬂuoresces 35
times brighter compared with the wild-type GFP fromwhich it was de-
rived, inserted under the control of a constitutively expressed cytomeg-
alovirus (CMV) promoter (Cormack et al., 1996). The eGFP transgene
was inserted in place of another deleted internal repeat sequence. As a
result of these genetic alterations, NV1066 has decreased virulence rel-
ative to the wild-type virus and can only successfully infect and repli-
cate in transformed, malignant cells. The virus is remarkably cancer
speciﬁc and infected cells display unmistakable bright green ﬂuores-
cence (major peak at 509 nm) (Chalﬁe et al., 1994).
2.2. Patients
From February 2007 toMay 2008, peritoneal washings were obtain-
ed prospectively from 96 patients undergoing diagnostic laparoscopy
for evaluation and staging of pancreatic adenocarcinoma at Memorial
Sloan-Kettering Cancer Center (MSKCC). All patients were at least
18 years of age and all presented to the Surgical Service with known
or presumed pancreatic cancer based on imaging studies and/or tissue
biopsy. Only patients who had histologically conﬁrmed pancreatic ade-
nocarcinomawere included in the clinical trial. Those pancreatic adeno-
carcinoma patients with an additional concomitant malignancy were
excluded from the study. For outcome results, all patientswere followed
for recurrence of cancer and survival for a minimum of 5 years.
2.3. Ethics
This study was reviewed and approved by the MSKCC institutional
review board (IRB). All patientswere required to provide informed con-
sent for participation in the study.
2.4. Laparoscopic Evaluation
Patients underwent staging laparoscopy under general anesthesia as
previously described (Wong and Coit, 2012; Kelly et al., 2009). In all
cases, a systemic examination of the peritoneal cavity was performed
after trocar insertion and CO2 insufﬂation. Peritoneal washing was
then performed immediately, prior to any surgical manipulation of tis-
sues. Normal saline was introduced into the right upper abdomen, left
upper abdomen, and pelvis. Gentle agitation was performed and theﬂuid was aspirated and collected separately from each site. Each of the
three patient samples was divided into two parts: half of the ﬂuid (ap-
proximately 30mL)was sent to the pathology department for cytologic
examination, and the other half was transported to the laboratory on ice
for evaluation with virus. For patients found to have ascites at laparos-
copy, ascites ﬂuidwas aspirated and collected from the three siteswith-
out instillation of normal saline.
2.5. Cytologic Assay
Samples brought to the pathology department for cytologic evalua-
tion were placed in Cytolyte ﬁxative (Cytyc Corp., Marlborough, MA)
and centrifuged for 10 min. The resulting cell pellet was ﬁxed with
PreservCyte (Cytyc Corp). Two slide preparations were made from
each sample using the Thin Prep procedure. One was stained with
H&E and the other with Papanicolaou stain. All cytologic preparations
were evaluated for the presence of malignant cells by attending
cytopathologists at Memorial Sloan-Kettering Cancer Center (MSKCC).
2.6. Virally Mediated Fluorescence Detection Assay
The samples were centrifuged for 5 min (8000 rpm) at 4 °C. After
centrifugation, the cell pellets were resuspended in 500 μL warm Ros-
well Park Memorial Institute (RPMI) media supplemented with 10%
fetal calf serum (FCS), 100 μg/mL penicillin, and 100 μg/mL streptomy-
cin. Samples were then infected with 1 × 106 PFU NV1066. Samples
were maintained at room temperature for 30 min after infection, at
which time an additional 500 μL of RPMI media was added. All samples
were then transferred to a humidiﬁed incubator suppliedwith 5%CO2 at
37 °C. Samples were incubated with virus for 12 to 18 h prior to evalu-
ation by ﬂuorescence microscopy or ﬂow cytometry.
2.7. Fluorescence Microscopy
Samples to be evaluated by ﬂuorescencemicroscopywere incubated
with virus in chamber slides (Lab-Tek II; Nalge Nunc, Rochester, NY).
After incubation, samples were systematically evaluated with a Zeiss
Axiovert 200M inverted standmicroscope (Carl Zeiss, Inc., Oberkochen,
Germany) with a 100 W mercury arc lamp light source and Retiga EX
CCD digital camera. Selective excitation of eGFP was produced through
a Chroma 41017 ﬁlter set after placement of both excitation and emis-
sion ﬁlters to detect eGFP. Images were processed and analyzed with
the MetaMorph Imaging System (Universal Imaging Corporation,
Downingtown, PA).
2.8. Flow Cytometry
Samples to be evaluated byﬂow cytometrywere incubatedwith virus
in polystyrene round-bottom tubes (BD Falcon, San Jose, CA). Standard
ﬂow cytometry was performed in accordance with guidelines outlined
in the 1995US–Canadian consensus conference. Data acquisition analyses
were performed on a FACScan ﬂow cytometer (BD Biosciences, San Jose,
CA). CellQuest software (Becton Dickinson Immunocytometry Systems,
San Jose, CA) was used for data analysis.
2.9. Characterization of eGFP-Positive Cells
To furthermolecularly characterize the green cells identiﬁed in peri-
toneal washings, virus-infected, eGFP-positive samples were incubated
with immunoﬂuorescent antibodies to cell surfacemarkers. R-PE conju-
gatedmouse antihuman anti-CD66 (BD Pharmingen, Franklin Lakes, NJ)
and mouse antihuman anti-HLA-DR (BD Pharmingen, Franklin Lakes,
NJ) were used to characterize eGFP-expressing cells in peritoneal wash-
ings. Samples were incubated with each antibody for 30 min at room
temperature prior toﬂuorescencemicroscopy examination. R-PE conju-
gated antibody was identiﬁed by detection of red ﬂuorescence under
Fig. 1. Fluorescentmicroscopic image of strongly eGFP-positive cells in peritoneal washing
from a patient with pancreatic cancer who had negative cytology (magniﬁcation 100×).
Table 1












Tx 11 11 0
T1–2 7 4 3
T3–4 64 35 29
LN metastasisa 29 13 16 0.78
Peritoneal metastasis 9 9 0 0.01
Hepatic metastasis 16 15 1 b0.01
Positive cytology 12 12 0 b0.01
Stagea 0.03
I–IIA 24 10 14
IIB–IV 58 40 18
Differentiation 0.76
Unknown 21 11 10
Well/moderate 46 30 16
Poor 15 9 6
Vascular invasion 27 15 12 0.07
Perineural invasion 34 16 18 1.00
Values in bold font are statistically signiﬁcant.
a Pathologic information was used when available for deﬁning T and N stages. When
pathology was not available, clinical staging information was used.
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zation of eGFP-expressing cells. Cells were ﬁxed and stained with a
mouse anti-human antibody to c-kit.
2.10. Statistical Analysis
eGFP status was reported as positive or negative and was correlated
with clinical and pathologic factors using the Chi-Square test for cate-
gorical variables, and the Mann–Whitney U test for continuous
variables. The probability of recurrence was estimated by the Kaplan–
Meiermethod and compared across groups using a log-rank test. Statis-
tical signiﬁcance was deﬁned by P b 0.05.
3. Results
3.1. Patient Demographics
From February 2007 through April 2008, peritoneal washings were
obtained from 96 patients undergoing diagnostic laparoscopy for pre-
sumed or biopsy-proven pancreatic cancer. Four patients were found
to have neuroendocrine tumors, ten had peri-pancreatic tumors (aris-
ing fromdistal commonbile duct or duodenalmucosa), and twohad be-
nign disease. The remaining82patients had pancreatic adenocarcinoma
and comprised the study population. Themedian age of this cohort was
67.5 years (range, 29–87 years). A total of 42 patients (51%) were fe-
male. Within the pancreatic adenocarcinoma group, 49% of patients
underwent laparoscopy with or without biopsy and/or celiac plexus
block (n = 40), 45% underwent resection (pancreaticoduodenectomy,
n = 30; distal pancreatectomy, n = 7). Lastly, 6% of patients (n = 5)
underwent a palliative bypass procedure with cholecystojejunostomy,
choledochojejunostomy, and/or gastrojejunostomy.
The tumor was in the head of the pancreas in 68% (n = 56) of pan-
creatic adenocarcinoma patients. The tumor was well differentiated in
2%, moderately differentiated in 54%, poorly differentiated in 18%, and
not assessed in the remaining 26%. Four percent (n = 3) had T1; 5%
(n= 4) had T2; 68% (n= 56) had T3; and 10% (n= 8) had T4 tumors.
A total of 11 patients (13%) had unknown T stage. Disease stages for the
pancreatic adenocarcinoma patients were as follows: IA—3 (4%), IB—2
(2%), IIA—19 (23%), IIB—27 (33%), III—4 (5%), and IV—27 (33%).
3.2. Conventional Cytology
Of the 82 patients with pancreatic adenocarcinoma, 12 (15%) had
positive cytology. Of these 12 patients, ten had visible liver (n = 2)
and/or peritoneal metastases (n = 8) conﬁrmed by tissue biopsy. Two
of the 12 had positive cytology as the only evidence of metastasis.
These two patients had T3 and T4 disease, and would have been stages
IIA and III, respectively, if not for the ﬁnding of positive cytology. Of 16
total patients with isolated liver metastases, two had positive cytology.
Of nine patients with isolated peritoneal or peritoneal and liver metas-
tases, eight had positive cytology. Cytology showed sensitivities of 44%
and 89% for detection anymetastatic disease and for detection of perito-
neal metastases, respectively.
3.3. eGFP Expression
Of the 82 patients with pancreatic adenocarcinoma, 50 (61%) had
virally-mediated strongly eGFP positive cells in peritoneal washings
(Fig. 1). Of these 50 patients, 26 (52%) had stage IV disease. Disease
stages for the remaining eGFP-positive patients were as follows: IA—2
(4%), IB—1 (2%), IIA—7 (14%), IIB—12 (24%), and III—2 (4%). All twelve
cytology-positive patients were also eGFP positive. Of the 16 patients
with isolated liver metastases, 15 were eGFP positive. All nine patients
with isolated peritoneal or peritoneal and liver metastases were eGFP
positive. HSV-mediated ﬂuorescence detection had sensitivities of 94%and 100% for detection of any metastatic disease and for detection of
peritoneal-based metastasis, respectively.
3.4. Correlation of Clinicopathologic Factors and eGFP Expression in
Peritoneal Washings
Table 1 summarizes the correlation between eGFP expression in
peritoneal washings and various clinicopathologic features including T
stage, presence of intraperitoneal metastases (hepatic and peritoneal),
cytology, stage, lymph node status, degree of differentiation, and the
presence of vascular/perineural invasion. Molecular diagnosis with vi-
rally mediated ﬂuorescence correlated signiﬁcantly with the presence
of hepatic (P b 0.005) and peritoneal (P=0.01)metastases, cytology re-
sults (P b 0.005), and disease stage (P= 0.027).
3.5. Molecular Characterization of eGFP-Positive Cells
eGFP-positive cells isolated by ﬂow cytometry were able to be fur-
ther characterized using ﬂuorescent antibodies to cell-surface markers,
and immunohistochemistry. Fig. 2A demonstrates strongly andweakly-
eGFP expressing cells in peritoneal washings from a patient with pan-
creatic cancer. The weakly-eGFP positive cells had dendrites and were
occasionally observed in both benign and malignant washings. These
cells were counter-stained with a ﬂuorescent antibody to HLA-DR,
conﬁrming them to be dendritic cells (Fig. 2B). Conversely, the round,
strongly positive cells were counterstained with a ﬂuorescent antibody
Fig. 2. (A) Fluorescent microscopic image of cells in peritoneal washing from a patient with pancreatic cancer, demonstrating large, round, strongly eGFP positive cells, and rare, weakly
eGFP positive cells with dendritic processes (10×). The cells were subsequently sorted by eGFP expression. The weakly eGFP positive cells were counter-stained with a ﬂuorescent
antibody to a human leukocyte antigen (HLA-DR), conﬁrming them to be dendritic cells (B; 100×). Conversely, the strongly eGFP positive cells counter-stained with an antibody to
CEA (C; 100×). eGFP positive cells isolated from a patient with metastatic gastrointestinal stromal tumor (GIST) were ﬁxed and stained with an antibody to c-KIT (D; 100×).
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metastatic GIST were positive for c-KIT on immunohistochemistry
(Fig. 2D).
3.6. Recurrence and Survival
Of the 82 pancreatic adenocarcinoma patients, a total of 33, all of
whom were cytology negative, underwent R0 resection. This group
was analyzed for intraperitoneal and any recurrence free survival
(RFS). At a median follow up of 15.4 months, 20 patients (61%) went
on to develop clinical recurrence. Within the eGFP-positive group, 75%Fig. 3.Kaplan–Meier curve demonstrating recurrence free survival for pancreatic cancer patient
median follow up of 15.4 months, eGFP positive patients had signiﬁcantly shorter time to intraof patients developed recurrence. The most common site of ﬁrst recur-
rence was the liver (n = 12), followed by the peritoneum (n = 4),
and the lung (n = 2) or local/nodal (n = 2). Of those patients with re-
current disease ﬁrst detected in the liver, nearly half also had evidence
of peritoneal disease. Median intraperitoneal and any recurrence free
survival were signiﬁcantly shorter in the eGFP positive group (6.5 ver-
sus 14.6 months, P b 0.01; 6.5 versus 12.2months, P=0.01; respective-
ly) (Fig. 3A and B). Disease speciﬁc survival was also shorter in the eGFP
positive patients but this difference did not reach statistical signiﬁcance
(18.3 versus 36.2 months; P= 0.19) (Fig. 4). On univariate analysis of
factors associated with recurrence and survival in 33 patients whos whounderwent R0 resectionwhowere eGFP positive (n=16) or negative (n=17). At a
peritoneal recurrence (A) and any recurrence (B) (P= 0.05, 0.02; respectively).
Fig. 4. Kaplan–Meier curve demonstrating disease speciﬁc survival for pancreatic cancer
patients who underwent R0 resection stratiﬁed by eGFP status. Median DSS was
clinically, but not statistically, signiﬁcantly shorter in the eGFP positive patients (18.3
versus 36.2 months; P= 0.19).
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ed with recurrence (O.R. 2.64, 95% C.I. 1.21–5.78; P=0.02). None of the
variables evaluated had a statistically-signiﬁcant association with dis-
ease speciﬁc survival (Table 2).
4. Discussion
Peritoneal micro-metastases are a common occurrence and portend
poor prognosis for many malignancies including ovarian, gastric, and
pancreatic cancer (Ferrone et al., 2006; Merchant et al., 1999; Bentrem
et al., 2005; Burke et al., 1998; Yachida et al., 2002; Yoshimura et al.,
1984). The current standard method of detection relies on cytologic
evaluation of harvested cells according to for cytomorphologic charac-
teristics of malignant transformation. This test is highly speciﬁc and
clinically relevant: positive results are associated with very poor prog-
nosis, early intraabdominal recurrence, and death (Jimenez et al.,
2000a; Gold et al., 2007; Ferrone et al., 2006; Merchant et al., 1999;
Bentrem et al., 2005; Burke et al., 1998; Yachida et al., 2002;
Yoshimura et al., 1984). However, when very few free cancer cells are
present in the peritoneum, they may be difﬁcult to identify by
cytomorphologic criteria alone. In addition, mesothelial atypia and in-
ﬂammatory inﬁltrates can complicate cytologic analysis of peritoneal
ﬂuid. Pancreatic and gastric cancer patients undergo DL with the goalTable 2
Univariate analysis of pathologic variables associated with recurrence and survival in pa-
tients undergoing R0 resection (N = 33).
Variable Recurrence free survival Disease speciﬁc survival
O.R. 95% C.I. P O.R. 95% C.I. P
eGFP positive 2.64 1.21–5.78 0.02 1.72 0.74–4.00 0.21
Tumor depth 0.25 0.46
T1–2 REF REF
T3 2.33 0.55–9.86 1.73 0.40–7.45 0.46
Positive lymph nodes 1.11 0.50–2.43 0.80 1.25 0.51–3.06 0.62
Differentiation 0.11 0.64
Well REF REF
Moderate/poor 2.05 0.85–4.94 1.21 0.52–2.85 0.65
Vascular invasion 1.97 0.79–4.93 0.15 1.53 0.52–4.53 0.44
Perineural invasion 1.37 0.18–10.17 0.76 1.81 0.23–14.35 0.57
Values in bold font are statistically signiﬁcant.of accurate preoperative staging and are often found to have false neg-
ative cytology. Many of these patients then undergo resection with cu-
rative intent only to develop early postoperative recurrence in the
peritoneal cavity.
NV1066-mediated eGFP expression has been shown to aid in detec-
tion of malignant deposits in preclinical animal models of pleural, peri-
toneal, and lymphatic disease, and in preparations of malignant cells
mixed with benign cells from various organs in vitro (Adusumilli
et al., 2005, 2006a, b, 2011; Eisenberg et al., 2006; Stanziale et al.,
2004). In the current study, we clinically test a virally-mediated ﬂuores-
cence detection assay with NV1066 was employed to detect peritoneal
micro-metastases in pancreatic cancer patients. In this cohort of pancre-
atic adenocarcinoma patients evaluated prospectively, virally-mediated
ﬂuorescence increased the yield of diagnosis of peritoneal micro-
metastasis by 46% over conventional cytology. This increased sensitivity
appears to be clinically relevant. Patients undergoing resection with cu-
rative intent, all ofwhomhadnegative conventional cytology, had ame-
dian recurrence free survival of only 6.5 months if eGFP positive, versus
12.2 months if eGFP negative (P=0.01). This ﬁnding conﬁrms that the
presence of eGFP positive cells in peritoneal washings is a sensitive indi-
cator of micrometastasis and that these cells do go on to develop into
early recurrence. As is true for pancreas cancer in general, the most
common site of ﬁrst clinical recurrence after curative-intent resection
for patients in this trial was the liver, followed by the peritoneum.
eGFP positivity predicted not only intraperitoneal, but any recurrence.
This ﬁnding suggests that the presence of eGFP positive cells may be
an indicator of aggressive tumor biology.Mediandisease speciﬁc surviv-
al for the eGFP-negative patients was 36.2 months, double that of eGFP-
positive patients. Although not statistically signiﬁcant, this survival is
comparable if not superior to the 20–24monthmedian survival expect-
ed after curative resection and adjuvant therapy. Median survival of this
magnitude for pancreatic cancer patients has only been reported in neo-
adjuvant therapy trials. This ﬁnding suggests that virally-mediatedﬂuo-
rescence detection of peritoneal micrometastasis may have an
important role in patient selection for surgery.
Virally-mediated ﬂuorescence detection can be incorporated into
the DL procedure with essentially no increased morbidity or risk to
the patient, and can enhance the sensitivity of detection of peritoneal
micrometastatic disease. This assay is inexpensive, rapid, and easy to
perform and interpret. eGFP positivity could potentially be incorporated
into DL for pancreatic cancer patients. If adopted into clinical practice,
eGFP positive patients, like those with positive cytology, could be of-
fered neoadjuvant or deﬁnitive systemic therapy. While this pilot
study focuses on pancreatic adenocarcinoma, there is reason to believe
that this highly sensitive and speciﬁc assay is applicable to essentially all
intraabdominal malignancies. Virallymediated ﬂuorescence has the po-
tential to enhance the sensitivity of DL for the detection of occult
micrometastatic disease for many cancers (Kemeny et al., 2006).
The virus tested in this study is one of a family of genetically
engineered viruses designed for speciﬁc infection and killing of cancer.
These were meant as therapeutic agents. In preclinical studies, these vi-
ruses infect and kill many cancer cell lines, including many pancreatic
cancer cell lines (Buijs et al., 2014; Dai et al., 2014; Haddad et al.,
2012; Liu et al., 2013; Yamamura et al., 2014). The current study indi-
cates that this virus infects and replicates in primary pancreatic cancer
cells from many different patients. In preclinical studies, the ability to
kill tumor is directly correlated to infectivity and replication
(Adusumilli et al., 2006b; Stanziale et al., 2004; Wong et al., 2002).
These observations suggest that herpes simplex oncolytic viruses
should be investigated not only as agents to improve staging andpatient
selection, but especially as novel treatment agents for pancreatic cancer,
a disease that is highly resistant to cytotoxic chemotherapy.
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